跳轉至內容
Merck
全部照片(1)

Key Documents

L6785

Sigma-Aldrich

乳酸胱氨酸

≥90% (HPLC), powder, proteosome inhibitor

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H24N2O7S
CAS號碼:
分子量::
376.43
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

乳酸胱氨酸, ≥90% (HPLC)

品質等級

化驗

≥90% (HPLC)

形狀

powder

效力

4 nM Ki (proteasome inhibitor)

溶解度

water: 10 mg/mL, clear, colorless

儲存溫度

−20°C

SMILES 字串

CC(C)[C@H](O)[C@]1(NC(=O)[C@H](C)[C@@H]1O)C(=O)SC[C@H](NC(C)=O)C(O)=O

InChI

1S/C15H24N2O7S/c1-6(2)10(19)15(11(20)7(3)12(21)17-15)14(24)25-5-9(13(22)23)16-8(4)18/h6-7,9-11,19-20H,5H2,1-4H3,(H,16,18)(H,17,21)(H,22,23)/t7-,9+,10+,11+,15-/m1/s1

InChI 密鑰

DAQAKHDKYAWHCG-RWTHQLGUSA-N

一般說明

乳酸菌素作为一种抗生素,是链霉菌的代谢物。

應用

使用乳胞素:
  • 作为蛋白酶体抑制剂,抑制蛋白质降解
  • 抑制细胞蛋白酶体活性,为活细胞成像
  • 阻断人单核细胞来源的树突状细胞(MoDC)中蛋白酶体蛋白水解长达24小时
  • 对动物进行单侧注射,诱导黑纹状体病变

生化/生理作用

乳酸菌素在小鼠神经母细胞瘤细胞系中具有抑制细胞周期发育、刺激分化等作用。它可以作为Clasto-乳胞素β-内酯的前体。细胞可透过性和不可逆蛋白酶体抑制剂(Ki = 4nM)。抑制NF-kB的活化(IC50 = 10mM)。在neuro2A小鼠神经母细胞瘤细胞中诱导神经突生长。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin A CENTRAL ROLE FOR clasto-LACTACYSTIN beta-LACTONE
Dick L R, et al.
The Journal of Biological Chemistry, 271(13), 7273-7276 (1996)
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer
Ruggeri B, et al.
Advances in Pharmacology, 57(13), 91-135 (2009)
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through Galphao/i-triggered proteasomal degradation of Rap1GAPII
Jordan J D, et al.
The Journal of Biological Chemistry, 280(12), 11413-11421 (2005)
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease
Vernon A C, et al.
PLoS ONE, 6(2), e17269-e17269 (2011)
Dallas S Shi et al.
The Journal of clinical investigation, 124(9), 3757-3766 (2014-07-26)
The proteasome inhibiter bortezomib has been successfully used to treat patients with relapsed multiple myeloma; however, many of these patients become thrombocytopenic, and it is not clear how the proteasome influences platelet production. Here we determined that pharmacologic inhibition of

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務